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Abstract
Introduction Although lobular carcinoma in situ (LCIS) has
traditionally been viewed as a marker of breast cancer risk,
recent clinical, pathological and genetic analyses have
supported the concept that LCIS is a low risk, direct precursor
of invasive lobular carcinoma. Global gene expression profiling
of LCIS has not been performed.
Methods We analysed the comprehensive gene expression
profile of a unique case of mass-forming LCIS using serial
analysis of gene expression (SAGE). This SAGE library is
publicly available online. By comparing the gene expression
profile of LCIS to that of benign breast epithelium and stroma,
we identified several genes up and down regulated in LCIS.
Differential expression of selected genes not previously studied
in LCIS was validated at the protein level by
immunohistochemistry and at the RNA level by quantitative
reverse transcriptase PCR (RT-PCR).
Results We identified down regulation of claudin 4 and
overexpression of matrix metalloproteinase 9 in LCIS relative to
normal breast epithelium and stroma. We validated these
findings by immunohistochemistry in a separate series of 11 and
19 LCIS cases, respectively. Overexpression of matrix
metalloproteinase 9 was further confirmed by quantitative RT-
PCR analysis of the index case.
Conclusions We have created the first global gene expression
profile of LCIS, and demonstrated down regulation of cell
junction proteins (an expected result) and overexpression of
matrix metalloproteinase 9 (an unexpected result). Additional
analysis of this data made available as an online resource should
facilitate further molecular characterisation of LCIS.
Introduction
Lobular carcinoma in situ (LCIS) is characterised by small, dis-
cohesive epithelial cells that fill, distend and distort the termi-
nal duct lobular units of the breast [1,2]. LCIS cells, which are
cytologically identical to those of invasive lobular carcinoma,
frequently contain mucin vacuoles, imparting a signet-ring cell
appearance. At the immunohistochemical level, the hallmark of
LCIS is loss of the expression of the E-cadherin protein, which
results in the loss of cohesion of the cells. Unlike ductal carci-
noma in situ (DCIS), a localised proven precursor to invasive
breast carcinoma, LCIS tends to be multifocal and bilateral,
and typically is neither calcified on mammography nor mass
forming on clinical or gross pathological examination. Instead,
LCIS is almost always an incidental microscopic finding iden-
tified by the pathologist. Less well-developed examples of the
same process, in which there is insufficient distention and
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distortion of the terminal duct lobular units, are classified as
atypical lobular hyperplasia (ALH).
Based on several classic studies that showed the invasive car-
cinomas that follow LCIS are often invasive ductal carcinomas
(IDC), and that the risk of breast cancer was almost equal in
each breast [3,4], LCIS has traditionally been viewed and
managed as a marker of bilateral breast cancer risk. However,
this concept is difficult to reconcile with several other clinical,
morphological and molecular observations that suggest that
LCIS is instead a cancer precursor. First, several other follow-
up studies have shown that the majority (three of four) of can-
cers that follow ALH and LCIS are in fact ipsilateral [5-9]. Sec-
ond, while many of the carcinomas that follow LCIS are IDCs,
invasive lobular carcinoma is over-represented in these cases.
It is possible that the frequent occurrence of IDC in patients
followed for LCIS may be explained by the frequent co-exist-
ence of LCIS and DCIS in these patients, with the DCIS acting
as the precursor to the IDC. In fact, when cases of pure LCIS
unassociated with concurrent DCIS are studied, the invasive
carcinoma that follows is almost always invasive lobular carci-
noma [10]. Third, it is not uncommon for LCIS to be associ-
ated with microinvasive lobular carcinoma [11], a morphology
that strongly suggests that the LCIS gives rise to the invasive
lobular carcinoma.
Finally, at the genetic level, multiple studies have shown simi-
larities between LCIS and invasive lobular carcinoma. Identical
activating mutations of the E-cadherin gene have been identi-
fied in concurrent LCIS and invasive lobular carcinoma
[12,13]. Array Comparative Genomic Hybridisation (CGH)
[14] and mitochondrial DNA analyses have demonstrated
marked similarities between matched LCIS and invasive lobu-
lar carcinoma, further supporting a clonal relationship. Moreo-
ver, LCIS demonstrates methylation of the same cancer
specific genes found in DCIS, IDC and invasive lobular carci-
noma [15]. Hence, many now view LCIS as a low-risk direct
precursor to breast cancer that tends to be bilaterally distrib-
uted [16,17]. Under this view, the more frequent bilateral dis-
tribution of LCIS accounts for the greater proportion of
contralateral cancers that follow LCIS as compared with
DCIS.
Given the growing view that LCIS represents a cancer precur-
sor, the identification of molecular alterations that suggest
potential therapeutic and chemopreventive targets within this
lesion is of great interest. At this point, studies have been lim-
ited by the typically small, microscopic extent of LCIS, which
precludes obtaining frozen tissue with intact, high-quality DNA
and RNA. At the DNA level, CGH studies have consistently
demonstrated loss of the long arm of chromosome 16, where
the E-cadherin gene is located [18,19]. RNA-based expres-
sion profiling analyses have not thus far been feasible.
In this study, we report the gene expression profile of a florid
case of LCIS by serial analysis of gene expression (SAGE).
SAGE provides an unbiased and quantitative assessment of
the cellular transcriptome, and it is a reliable tool for identifying
differentially expressed transcripts in cancer. In the remarkable
case studied, the LCIS formed a mass lesion, such that frozen
tissue could be obtained for genetic analysis. We validate sev-
eral up and down regulated genes at the RNA and protein
level, and identify dysregulated pathways in this unusual can-
cer precursor.
Materials and methods
Institutional Review Board approval
This study was approved by the Institutional Review Board of
the Johns Hopkins Hospital. The study met the exemption cri-
teria for human subject research because it involved the study
of existing pathological specimens, and the information was
recorded in such a manner that subjects could not be
identified.
SAGE library preparation
The patient was a post-pubertal, pre-menopausal (further
details available [20]) female who presented with a breast
mass. Excision demonstrated a 5 cm, ill-defined mass that dis-
played the classic morphological features of LCIS. Specifi-
cally, the lobular units were filled, distended and distorted by
discohesive small cells that frequently demonstrated intracyto-
plasmic mucin vacuoles (signet-ring cells). Immunohistochem-
istry for E-cadherin protein revealed an absence of labelling
within the LCIS cells, with preserved membranous labelling in
adjacent intact benign ductal epithelium. In some foci, the
LCIS demonstrated ductal extension and focal central necro-
sis. Unusual features of this lesion included a relatively high
mitotic rate within the lesion (average one mitosis per high
power field) and focally prominent perilobular oedema and
fibrosis. The latter was likely to account for the lesion being
grossly evident (Figure 1). Despite extensive sampling on fro-
zen and permanent sections, no evidence of invasion was
identified. The remaining waste tissue from the optimal con-
trolled temperature medium (OCT)-embedded cytomolds
used for frozen section, along with frozen samples of ipsilateral
and contralateral benign breast tissue, were the materials
used for this study.
Frozen sections were prepared from several areas of the lesion
and ipsilateral and contralateral normal breast tissues. On
these H & E-stained frozen section slides, areas of LCIS were
well delineated from the benign fibrous and fatty mammary
stroma, so that they could be circled with a marking pen. No
invasive carcinoma was identified on these serial frozen sec-
tion slides. To enrich for LCIS cells, the OCT-embedded fro-
zen tissue blocks from which these slides were made were
macrodissected grossly, using a scalpel blade and a marked
H&E-stained frozen section slide as a guide. Circled areas
consisting of approximately 75% LCIS cells were manually cutAvailable online http://breast-cancer-research.com/content/10/5/R91
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out from the OCT-embedded frozen tissue blocks (Additional
file 1), and RNA was extracted from these enriched samples to
create the LCIS SAGE library. Additionally, normal lobules
from the ipsilateral and contralateral breast were circled and
macrodissected in the same fashion to enrich for epithelium
for comparative quantitative reverse transcriptase PCR (RT-
PCR) analysis.
SAGE provides unbiased and quantitative analysis of the cel-
lular transcriptome. In contrast to microarrays, SAGE does not
require  a priori knowledge of the queried transcripts, and
therefore allows for both quantification of gene expression and
for gene discovery. SAGE libraries consist of short nucleic
acid sequences or 'tags' that are concatemerised for the pur-
poses of sequencing. SAGE tags correspond to unique tran-
scripts or expressed sequences in the transcriptome, and the
frequency of a given tag within the library corresponds to the
abundance of its corresponding transcript.
Total RNA from the frozen enriched LCIS was isolated using
the uMACS kit (Miltenyi Biotec, Germany) as per the manufac-
turer's instructions. A long (17 bp) SAGE (LSAGE) library was
constructed using NlaIII as the anchoring enzyme and Mme I
as the tagging enzyme, as previously described [21]. 2304
pZero-1 plasmid clones were sequenced as part of the Can-
cer Genome Anatomy Project's (CGAP) SAGE project [20].
The CGAP 'SAGE Tag Extraction Tool' was used to extract
SAGE tags and linker sequences used in library construction.
Human SAGE libraries were generated at an approximate res-
olution of 50,000 SAGE tags per library or more, and as a
'first-pass' filtration, tags occurring only once or with multiple
annotations to the genome were removed from further analy-
sis. Prior to analysis, all SAGE libraries were normalised to
200,000 tags.
LCIS cases used for validation of SAGE data
Immunohistochemical labelling was performed on formalin-
fixed, paraffin-embedded tissue blocks of 18 well-character-
ised, typical cases of LCIS, all of which were reviewed by a
dedicated breast pathologist (PA), along with the index case
(19 total cases). The LCIS cases featured monomorphic, dis-
cohesive cells with focal cytoplasmic vacuolisation that filled,
distended and distorted lobular units. Aside from the index
case, none of these typical cases demonstrated necrosis, ple-
omorphism or increased mitotic activity. Seven of these LCIS
cases were associated with an invasive lobular carcinoma,
while the other 12 were unassociated with invasive carcinoma.
The four cases of this group that were analysed for E-cadherin
expression by immunohistochemistry were, as expected, neg-
ative. The other cases were not analysed because their mor-
phology was so characteristic.
Immunohistochemistry methods
Briefly, 4 μm sections were deparaffinised in xylene for 30 min-
utes and rehydrated using graded ethanol concentrations.
Immunohistochemical labelling was performed using the avi-
din-biotin peroxidase complex technique and 3',3'-diami-
nobenzidine as chromagen. The antibodies used, vendors,
clones, retrieval methods and dilutions were as follows: matrix
metalloproteinase 9 (MMP9) (Vector Laboratories, Burlin-
game, CA, USA, VP-M6444, clone 2C3, microwave retrieval
in citrate buffer, 1:40 dilution), matrix metalloproteinase 2
(MMP2) (Labvision, Fremont, CA, USA Catalog #RB-9233-
P0; microwave retrieval in citrate buffer, 1:50 dilution) and
claudin 4 (Zymed Laboratories, San Francisco, USA, Clone
3E2C1, steam in citrate buffer, 1:100 dilution).
Quantitative RT-PCR
Both normal and tumour RNA were extracted using the Trizol
method, and all cDNAs were prepared with 1 μg of RNA in
SuperScript II (Invitrogen, Carlsbad, CA) reactions according
to the instructions of the manufacturer. Real-time SYBR green
RT-PCR (Invitrogen, Carlsbad, CA) was performed on an
Applied Biosystems PRISM 7900. Amplifications of MMP2,
MMP9 and internal control gene GAPDH were performed with
the following primer pairs: MMP2, forward 5'-AGATTCCAGA-
GAGTGGCTCCTC-3' and reverse 5'-GTAAGAAAGGT-
TCTAAGGCAGCC-3'; MMP9, forward 5'-
CCAGCTGTATTTGTTCAAGGATG-3' and reverse 5'-CTT-
TCTCTCGGTACTGGAAGACG-3'; and GAPDH, forward 5'-
GAAGATGGTGATGGGATTTC-3' and reverse 5'-GAAGGT-
GAAGGTCGGAGTC-3'.
Figure 1
Pathology of the index case Pathology of the index case. (a, b) Low power view showing terminal 
ductal lobular units distended by small discohesive cells, typical of lob-
ular carcinoma in situ (LCIS). Note the prominent perilobular oedema 
and fibrosis. (c) Higher power view showing discohesive nature of 
LCIS cells and focal intracytoplasmic vacuoles (signet-ring cells). (d) E-
cadherin protein is absent in the LCIS cells by immunohistochemistry, 
confirming the diagnosis. Note the intact labelling in residual duct epi-
thelial cells, providing an internal control.Breast Cancer Research    Vol 10 No 5    Cao et al.
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Results
Identification of differentially expressed SAGE tags in 
LCIS
In the LCIS LSAGE library, 67,834 SAGE tags were iterated.
The data is available online [20]. To determine which genes
were expressed differentially between LCIS and normal breast
epithelium, we used the online SAGE Digital Gene Expression
Displayer (DGED) program to compare the LCIS LSAGE
library with pooled LSAGE libraries prepared from normal duct
epithelial cells (LSAGE-Breast-
normal_epithelium_CD44+_AP_N1 (56,008 tags),
LSAGE_Breast_normal_epithelium_CD24+_AP_N2 (41,430
tags), LSAGE_Breast_normal_epithelium_CD24+_AP_N1
(41,551 tags)), myoepithelial cells
(LSAGE_Breast_normal_myoepithelium_AP_IDC7(69,006
tags)) and stroma (LSAGE_Breast_normal_stroma_B_IDC8
(50,485 tags)). Our rationale was that the enriched LCIS sam-
ple we used for SAGE still contained some contaminating nor-
mal breast stroma and myoepithelium, so inclusion of stromal
and myoepithelial SAGE libraries in the comparison would
negate their contribution and allow meaningful distinctions
between LCIS cells and normal breast epithelial cells. Using
this DGED analysis, 223 tags that were differentially
expressed by two-fold at a p value of 0.05 were identified. Of
these tags, 110 were overexpressed by two-fold, with 123
underexpressed by two-fold. We used the online Digital North-
ern function to demonstrate the relative expression of genes of
interest from this list in these and other online LSAGE libraries
derived from different breast lesions. We selected genes to
validate based on biological relevance and availability of well-
characterised commercial antibodies for
immunohistochemistry.
Known genes found to be differentially expressed in the 
LCIS LSAGE library
Initial analysis of the LCIS LSAGE library results revealed con-
cordance with the published literature on LCIS. First, E-cad-
herin was noted to be down regulated compared with the
three LSAGE libraries derived from normal mammary epithe-
lium, concordant with the known inactivation of E-cadherin in
almost all LCIS and the absence of E-cadherin expression in
the sample used to generate this LSAGE library (Additional file
2). Additionally, alpha-catenin and delta-catenin expression
was not detected in the LCIS LSAGE library, while they were
abundantly expressed in the normal duct epithelial cell LSAGE
libraries. These results are consistent with multiple published
studies demonstrating that LCIS is associated with inactiva-
tion and disruption of the entire E-cadherin complex, including
alpha-catenin, beta-catenin and p120-catenin [22-25]. Finally,
cyclin D1 was noted to be overexpressed in the LCIS LSAGE
library compared with normal luminal epithelium. Although ini-
tial studies had suggested the cyclin D1 was overexpressed in
invasive lobular carcinoma but not LCIS [26], more recent
studies have shown up regulation of cyclin D1 in LCIS [27].
We also found up regulation of cyclin D1 in four cases of LCIS
relative to normal duct epithelium by immunohistochemistry
(data not shown).
Identification and validation of novel differentially 
expressed genes in the LCIS LSAGE library
Claudin 4
Claudins are tight junction proteins that are aberrantly
expressed in several human cancers [28-30]. Claudin 4 was
noted to be down regulated in the LCIS SAGE library com-
pared with the five pooled normal libraries using the DGED
program, and underexpressed compared with all other librar-
ies derived from benign and malignant breast epithelium using
the Digital Northern function (Figure 2). Therefore, we exam-
ined a series of well-characterised cases of LCIS for claudin 4
expression by immunohistochemistry. Claudin 4 was noted to
be underexpressed compared with the normal mammary epi-
thelium, which showed membranous labelling in nine of 11
cases of LCIS (Figure 3), with expression at similar levels in
two of 11 cases. Four of these cases were associated with
concurrent invasive lobular carcinoma. In two of these four
invasive lobular carcinomas, claudin 4 was also underex-
pressed, whereas in the other two expression in the invasive
lobular carcinoma was at the same level as that seen in normal
mammary epithelium. Of note, E-cadherin protein expression
was negative in both cases of LCIS in which claudin 4 expres-
sion was not down regulated.
For comparison, we also labelled eight cases of DCIS for clau-
din 4. Consistent with the prior literature [31], up regulation of
claudin 4 was identified in four of eight cases, whereas in two
of eight cases claudin 4 expression was at similar levels in the
DCIS and normal ductal epithelium. In the other two cases,
expression of claudin 4 was variable within different ducts har-
boring DCIS. We were able to obtain serial sections harboring
these same DCIS-bearing ducts from one of these cases, and
demonstrated variable E-cadherin expression in the DCIS
which mirrored that of claudin 4 (Figure 4). Areas underex-
pressing E-cadherin also underexpressed claudin 4. Hence, in
almost all LCIS and at least some cases of DCIS, the expres-
sion of claudin 4 parallels that of E-cadherin.
Matrix metalloproteinases
MMPs are postulated to be important in the degradation of
basement membrane and extracellular matrix during cancer
cell invasion. In particular, MMP9 and MMP2 are involved in
the degradation of type 4 collagen, which comprises base-
ment membranes, a process thought to be important in the
development of invasive carcinoma and metastasis [32,33].
Using the DGED program, MMP9 was noted to be overex-
pressed in the LCIS LSAGE library compared with the pooled
normal libraries, and overexpressed compared with all SAGE
libraries derived from benign and malignant ductal epithelium
using the Digital Northern function (Figure 5).Available online http://breast-cancer-research.com/content/10/5/R91
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Therefore, we performed immunohistochemistry for MMP9 on
a series of 19 cases of LCIS with adjacent normal breast epi-
thelium. In normal lobules, MMP9 labelling was noted to be
weak in the normal myoepithelium; the normal luminal epithe-
lium was generally negative, although weak labelling was
occasionally seen. Consistent with previous observations
[33], strong MMP9 expression was consistently noted in mac-
rophages comprising biopsy cavities, which were seen in sev-
eral sections, and moderate labelling of the smooth muscle of
medium caliber blood vessels was also appreciated. We dem-
onstrated up regulation of MMP9 relative to normal duct lumi-
nal epithelium in 15 of 19 cases (Figure 6), with the remaining
four cases of LCIS showing expression similar to that of nor-
mal luminal epithelium.
In contrast, there was a less impressive suggestion of MMP2
overexpression in LCIS relative to normal luminal epithelium
using the DGED function; however, stromal and myoepithelial
libraries expressed more MMP2 than the LCIS library did, rais-
ing the possibility that the small difference was artifactual and
due to stromal contamination (Additional file 3). Therefore, we
performed immunohistochemistry on a series of nine cases of
LCIS, and found that MMP2 was overexpressed in only one
case, whereas it was expressed at equivalent levels to normal
epithelium in the other eight (data not shown). Hence, the
immunohistochemical results for MMP9 and MMP2 correlated
well with the SAGE results.
To further validate the overexpression of MMP9 in LCIS, we
performed quantitative RT-PCR for MMP2 and MMP9 on mac-
rodissected frozen LCIS, ipsilateral normal lobules and con-
tralateral normal lobules from the index case. This analysis
demonstrated that only MMP9, and not MMP2, was overex-
pressed in LCIS, again concordant with SAGE and immuno-
histochemical results (Figure 7).
Discussion
SAGE is an unbiased and quantitative method of identifying
differentially expressed transcripts in human cancer, enabling
discovery of cancer biomarkers, therapeutic and chemopre-
ventive targets. For example, in 2001, SAGE was used to first
demonstrate that mesothelin [34] and prostate stem cell anti-
gen (PSCA) [35] were overexpressed in pancreatic adenocar-
cinoma. Mesothelin and PSCA have subsequently been
utilised as adjuncts in diagnosis, as candidate serum biomark-
ers and as targets of pancreatic cancer immunotherapy. We
report herein the first SAGE analysis of LCIS. Such studies
Figure 2
Digital Northern blot of claudin 4 expression in breast long serial analysis of gene expression (SAGE) libraries Digital Northern blot of claudin 4 expression in breast long serial analysis of gene expression (SAGE) libraries. Note that the lobular carci-
noma in situ (LCIS) library shows lower expression of claudin 4 than all of the other breast epithelial and stromal libraries, with the exception of a sin-
gle myofibroblast library.Breast Cancer Research    Vol 10 No 5    Cao et al.
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have previously not been possible because of the microscopic
nature of LCIS.
The unique nature of the index case of this study, specifically
the fact that it formed a mass, allowed the lesion to be identi-
fied grossly such that a small amount could be frozen for gene
expression studies. Although our study is somewhat limited by
the fact that the analysis is only of a single LCIS case with
some unusual features (mass-forming lesion, central necrosis),
the LCIS LSAGE library demonstrated differential expression
of several genes (E-cadherin, cyclin D1), which was concord-
ant with the published literature on these genes in LCIS. More-
over, we validated the results immunohistochemically for novel
genes that are both up regulated (MMP9) and down regulated
(claudin 4) relative to normal ductal epithelium on a larger
series of more typical LCIS cases. Therefore, we believe our
results are more globally applicable to LCIS and that altera-
tions identified in other pathways not specifically validated in
this study are nonetheless very likely to be significant.
One key theme of our SAGE analysis was the observed down
regulation of cellular junctional proteins in LCIS. Such down
regulation should have been expected. Epithelial cell junctions
are comprised of both tight and adherens type junctions. Inac-
tivation of the E-cadherin protein, a key component of the
adherens junction that interacts with the actin cytoskeleton via
binding of alpha, beta and delta catenins, is a hallmark of LCIS.
Previous studies have demonstrated inactivation of the entire
E-cadherin complex in LCIS, including loss of expression of
alpha-catenin and membrane to cytoplasmic translocation of
p120 catenin [22-25]. Therefore, the down regulation of E-
cases in the validation set is consistent with the published lit-
erature, and supports the concept that the adherens junction
complex is inactivated in LCIS.
The loss of the tight junction protein claudin 4, validated by
immunohistochemistry in this study, has not been previously
reported in LCIS. However, these results are concordant with
current knowledge of claudin biology and the known expres-
sion pattern of claudin 4 in related carcinomas. First, at the cel-
lular level, tight junction formation is thought to depend on
intact adherens-based intercellular contacts [36]. Therefore,
because of the absence of E-cadherin and therefore the
absence of a functional adherens junction in LCIS, the
absence of tight junctions (and therefore claudin 4) should be
expected. The striking parallel expression of E-cadherin and
claudin 4 on serial sections of the remarkable case of DCIS
analysed in this study (Figure 4) further supports the notion
that the expression of E-cadherin and claudin 4 proteins is
tightly linked.
Second, although no previous study has examined LCIS, sev-
eral studies have examined expression of claudin 4 in invasive
lobular carcinoma. Two studies reported intact claudin 4
expression in invasive lobular carcinoma [37,38]; however,
these studies did not compare expression with the normal
duct epithelium, and used as little as 10% labelling as a crite-
rion for positivity. The one study that compared labelling to that
of the normal duct epithelium reported down regulation of
claudin 4 in two of two cases of invasive lobular carcinoma
[39]. Moreoever, it has been reported that diffuse gastric-type
adenocarcinoma, which cytologically and immunohistochemi-
cally resembles invasive lobular carcinoma in that it is com-
Figure 3
Claudin 4 immunohistochemistry (IHC) in separate lobular carcinoma in  situ (LCIS) cases Claudin 4 immunohistochemistry (IHC) in separate lobular carci-
noma in situ (LCIS) cases. (a) H & E section of LCIS case 1. (b) Clau-
din 4 IHC of LCIS case 1. Note the intact labelling of undermined 
residual strips of luminal epithelium and diminished expression in LCIS 
cells. (c) H & E section of LCIS case 2. (d) Claudin 4 IHC of LCIS case 
2. Note the intact labelling of residual luminal epithelium and diminished 
expression in LCIS cells which undermine the luminal epithelium.
Figure 4
Claudin 4 immunohistochemistry in a ductal carcinoma in situ (DCIS)  case Claudin 4 immunohistochemistry in a ductal carcinoma in situ 
(DCIS) case. (a, c) Claudin 4 is intact in the duct of DCIS at the right, 
but diminished in the duct of DCIS to the left. (b, d) Expression of E-
cadherin parallels that of claudin 4, greater in the duct to the right and 
diminished in the duct to the left.Available online http://breast-cancer-research.com/content/10/5/R91
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posed of discohesive signet-ring cells that lack E-cadherin
protein expression, demonstrates down regulation of claudin 4
protein [40,41]. Hence our results with LCIS are consistent
with those seen in related invasive carcinomas.
Importantly, these results have therapeutic implications. Our
group has shown that claudin 4 is up regulated in IDC, and is
a proposed target for therapy and chemoprevention [31]. Our
results show that such an approach may not be applicable to
LCIS or to invasive lobular carcinoma, because these lesions
typically underexpress claudin 4 relative to normal breast
epithelia.
In contrast, we were surprised by the overexpression of MMPs
in LCIS, and therefore we thought that it was important to val-
idate and verify this result using multiple methods. Indeed, we
show herein that MMP9 is over expressed at the RNA and pro-
tein level in LCIS by quantitative RT-PCR and immunohisto-
chemistry, respectively. No previous study has systematically
evaluated MMP9 expression in LCIS. However, one study did
find overexpression in invasive lobular carcinoma relative to
IDC, and noted that a single case of concurrent LCIS also
showed MMP9 expression [42].
Moreover, recent data in ovarian and pulmonary carcinomas
has suggested a causal inverse relationship between E-cad-
herin and MMP9 expression, which would fit our finding of high
MMP9 expression in LCIS that characteristically lacks E-cad-
herin [43,44]. MMPs are postulated to be important in the deg-
radation of basement membrane and extracellular matrix
during cancer cell invasion. In particular, MMP9 and MMP2
(also know as gelatinases) are involved in the degradation of
type 4 collagen that comprises basement membranes, a proc-
ess thought to be important in the development of invasive car-
cinoma and metastasis. Although degradation of basement
membranes is not a function that is concordant with the usual
clinical behaviour of LCIS (a non-invasive, low-risk cancer pre-
cursor), we suspect that the activity of MMP9 in LCIS must be
tightly regulated. Indeed, MMP2 and MMP9 are secreted as
zymogens and cleaved to their active form, and their activity is
tightly regulated by several mechanisms, including the actions
of tissue inhibitors of metalloproteinases (TIMPS). It is cer-
tainly conceivable that the expression of activated MMP9
helps effect the characteristic, permeative, 'Indian file' growth
pattern of invasive lobular carcinoma. Our study indicates that
MMP9 RNA and protein is already present at the precursor
(LCIS) stage of invasive lobular carcinoma, and raises the pos-
Figure 5
Digital Northern blot of matrix metalloproteinase (MMP) 9 expression in breast long serial analysis of gene expression (SAGE) libraries Digital Northern blot of matrix metalloproteinase (MMP) 9 expression in breast long serial analysis of gene expression (SAGE) libraries. 
Note that the lobular carcinoma in situ (LCIS) library shows higher MMP9 expression than all of the other breast epithelial and stromal libraries, with 
the exception of a single phyllodes tumour-derived library.Breast Cancer Research    Vol 10 No 5    Cao et al.
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sibility that factors leading to its activation may play a role in
the development of invasive disease. MMP9 therefore repre-
sents an interesting therapeutic [32] and chemopreventive tar-
get for patients with lobular neoplasia, both invasive and non-
invasive.
Finally, we note that the down regulation of cell junction pro-
teins (such as E-cadherin and claudin 4) and up regulation of
MMP9 that we observed may be taken by some to be evidence
of so-called epithelial-mesenchymal transition in LCIS. Indeed,
the transcription factor Twist is known to down regulate E-
cadherin expression in invasive lobular carcinoma, and is pos-
tulated to be a master regulator of epithelial-mesenchymal
transition and metastasis [45,46]. Although we agree that the
abnormalities we have elucidated in LCIS in this study do over-
lap with those described in vitro in epithelial-mesenchymal
transition, LCIS remains a cytokeratin-positive, epithelial
neoplasm.
Conclusions
In conclusion, an unbiased analysis of the LCIS transcriptome
by SAGE has identified MMP9 overexpression and claudin 4
underexpression. This LSAGE library is publicly available at
the Cancer Genome Anatomy Project SAGE website [20],
and should facilitate further, much needed research on this
enigmatic lesion.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
PA, DC and SS conceived of the study. PA drafted the manu-
script. KP carried out the SAGE data analysis. MKH, CID, JH,
HN and ADM carried out the immunohistochemical analysis.
XW and SS carried out the quantitative RT-PCR. NK carried
out macrodissection of LCIS and benign tissue used for quan-
titative RT-PCR. All authors read and approved the final
manuscript.
Additional files
Figure 6
Matrix metalloproteinase (MMP) 9 immunohistochemistry (IHC) on sep- arate lobular carcinoma in situ (LCIS) cases a and b Matrix metalloproteinase (MMP) 9 immunohistochemistry (IHC) on 
separate lobular carcinoma in situ (LCIS) cases a and b. LCIS cells 
show greater immunoreactivity than strips of undermined normal duct 
epithelium, which are essentially negative in each case.
Figure 7
Quantitative reverse transcriptase (RT) PCR for matrix metalloprotein- ase (MMP) 2 and MMP9 expression in the index case Quantitative reverse transcriptase (RT) PCR for matrix metallopro-
teinase (MMP) 2 and MMP9 expression in the index case. RNA was 
extracted from macrodissected lobular carcinoma in situ (LCIS), adja-
cent normal (AN) and contralateral normal (CN) lobules. Quantitative 
RT-PCR for MMP2, MMP9 and the housekeeping gene (GAPDH) was 
performed. Note the increased expression of MMP9 but not MMP2 in 
the LCIS versus the normal duct epithelial samples.
The following Additional files are available online:
Additional file 1
A TIF file containing a figure of the macrodissection of 
LCIS from frozen tissue of the index case. (a) On low 
power of frozen section guide slide, the LCIS areas are 
easily distinguished from the benign epithelium. (b) The 
area circled, which is enriched for LCIS, was cut out of 
the OCT-embedded frozen tissue block. RNA was 
extracted from this tissue for SAGE.
See http://www.biomedcentral.com/content/
supplementary/bcr2189-S1.tiff
Additional file 2
A TIF file containing a figure of the Digital Northern blot 
of E-cadherin expression in breast L-SAGE libraries. 
Note that the LCIS library shows lower expression of E-
cadherin than all of the other normal breast epithelial 
libraries.
See http://www.biomedcentral.com/content/
supplementary/bcr2189-S2.tiffAvailable online http://breast-cancer-research.com/content/10/5/R91
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